Pharma Stock In Focus As Board To Meet Regarding Funding Proposal Post Stock-Split

Sudarshan Pharma Industries Ltd, a top developing generic formulation and specialty chemical contract manufacturer, posted an almost 22 percent increase in post-tax profit to Rs 5.9 for H1FY25 as per the latest exchange filing. The figure, which is a considerable decline, is attributed to an almost over 1.7 percent drop in operations revenue amounting to Rs 227.8, however, the spawning EBITDA margin did surge for the company, rising from three points six to around seven point three percent.

SPIL filed an announcement formalizing a Rapid Funding Meeting between the company's board, set to take place on January 10 2025. The meeting will cover the topics of Securitized Fund, Convertible Fund and different ways to maximize the company's capital in order to survive within regulatory violating criteria.

On November 22, 2023, the company conducted a stock split that converted its Rs 10 equity shares to Rs 1 equity shares, which further increased the liquidity of the company. The stock gave a stunning 819 percent return from its 5.82 Rs 52-week low. Currently, SPIL has a market capitalization of Rs 1,260 crore and had a remarkable CAGR of 37 percent profit growth for the past five years.

Recently Sethia Pharma International Limited extended its geographical presence into Singapore's market by acquiring Sudarshan Pharma Industries Private Limited for 10,000 SGD. This acquisition was seamless as it required no major regulatory approvals and strengthened the company's presence. It also gained a 51 percent share of Ishwari Healthcare Private Limited which is a manufacturer and distributor of medical and surgical instruments which is now its subsidiary.

SPIL is a relatively new company founded in 2008 and is currently headquartered in Mumbai, India wherein it specializes in the sale of oil, specialty chemicals, intermediates, API, pharmaceutical generic and bulk selling. Vimac Healthcare the sub-division of SPIL sells branded products, as such they strategically sell their services to healthcare institutions and business organizations. SPIL Indian is known for its wide range of brand Kimox 96 range. 56 of which are registered in the R trademark which shows the variety of products the company offers.

SPIL works closely with the best pharmaceutical companies in India, providing contract manufacturing services for medicines and formulations. Together with their joint ventures and other activities, SPIL has made a solid place in the industry and contributes to growth and innovation.

They performed well in H1FY25 and have intentions to raise more funds, which will help them solidify their position in the market and grow their presence in other countries too.